Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The trial is a single-centre, randomized, double-blind, phase 1b trial of multiple ascending
doses of ZP4207 administered s.c. to healthy volunteers (HV) to evaluate the safety,
tolerability, pharmakocinetic (PK) and pharmacodynamic (PD). Three cohorts of 8 subjects are
planned. Within each cohort, the subjects will be randomly assigned to five repeated doses of
ZP4207 or placebo in a 3:1 treatment allocation at trial site.